Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Giannini S, Passeri G, Tripepi G, Sella S, Fusaro M, Arcidiacono G, Torres MO, Michielin A, Prandini T, Baffa V, Aghi A, Egan CG, Brigo M, Zaninotto M, Plebani M, Vettor R, Fioretto P, Rossini M, Vignali A, Fabris F, Bertoldo F
Nutrients · 53 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2021-01-14 · Nutrients · vol. 13 · issue 1 · p. 219
- Publisher
- Multidisciplinary Digital Publishing Institute
- Cited
- 84 citations · more than 96% of similar papers · 5.0× the field average
- Impact
- Top 10% most cited in its field
- References
- 66 works
- Access
- Open access (journal) · CC-BY
- Research areas
- COVID-19 Clinical Research Studies · Long-Term Effects of COVID-19 · Vitamin D Research Studies
- Keywords
- Medicine, Intensive care unit, Coronavirus disease 2019 (COVID-19), Cholecalciferol, Retrospective cohort study, Internal medicine, Vitamin D and neurology, Bolus (digestion), Gastroenterology, Pediatrics, Disease, Infectious disease (medical specialty)
- MeSH
- humans, vitamin d deficiency, cholecalciferol, vitamins, treatment outcome, hospitalization, injections, intravenous, retrospective studies, roc curve, adult, aged, aged, 80 and over, middle aged, female, male, covid-19, covid-19 drug treatment
21 authors
From IT
- Sandro Giannini · correspondingUniversity of Padua
- Giovanni PasseriUniversity of Parma
- Giovanni TripepiIstituto di Fisiologia Clinica; National Research Council
- Stefania SellaUniversity of Padua
- Maria FusaroUniversity of Padua; Istituto di Fisiologia Clinica; National Research Council
- Gaetano Paride ArcidiaconoUniversity of Padua
Abstract
Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000 IU bolus oral cholecalciferol (200,000 IU administered in two consecutive days) and the composite outcome (transfer to intensive care unit; ICU and/or death) was recorded. Ninety-one patients (aged 74 ± 13 years) with COVID-19 were included in this retrospective study. Fifty (54.9%) patients presented with two or more comorbid diseases. Based on the decision of the referring physician, 36 (39.6%) patients were treated with vitamin D. Receiver operating characteristic curve analysis revealed a significant predictive power of the four variables: (a) low (p p = 0.033) and propensity score-adjusted analyses (p = 0.039), so the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden. This hypothesis-generating study warrants the formal evaluation (i.e., clinical trial) of the potential benefit that cholecalciferol can offer in these comorbid COVID-19 patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.